Dr. Craig Basson joined Novartis in 2010 and is Vice President and Global Head of Translational Medicine (Cardiovascular and Metabolism) for the Novartis Institute for Biomedical Research.
His team is comprised of talented physician-scientists dedicated to developing novel therapeutics for cardiovascular and metabolic (CVM) disorders. The CVM team in Translational Medicine is responsible for devising new strategies to assess early efficacy of drugs designed to improve survival and quality of life for patients who suffer from these disorders as well as for identifying specific patient population subsets that will benefit from these drugs.
Craig T. Basson graduated from Washington University in St. Louis, was awarded a Marshall Scholarship at the University of Oxford, and then completed his MD and PhD at Yale University School of Medicine. Dr. Basson trained in Internal Medicine at Johns Hopkins Hospital and subsequently completed his clinical Cardiology fellowship at Harvard University and the Brigham and Women’s Hospital along with a research fellowship in human genetics. He began his independent laboratory there before moving to Cornell University Medical College. At Cornell, Craig assumed roles with increasing responsibility and most recently was Gladys and Roland Harriman Professor of Medicine, Director of the Center for Molecular Cardiology, and the Director of Cardiovascular Research. Craig was highly recognized for deciphering the molecular genetic basis of inherited congenital and adult onset cardiovascular disease and received several honors including election to the American Society of Clinical Investigation and designation as an Established Investigator of the American Heart Association.